

# Inositol 1,4,5-tris-phosphate activation of inositol tris-phosphate receptor $\text{Ca}^{2+}$ channel by ligand tuning of $\text{Ca}^{2+}$ inhibition

DON-ON DANIEL MAK\*, SEAN MCBRIDE\*, AND J. KEVIN FOSKETT\*<sup>†‡</sup>

\*Department of Physiology and <sup>†</sup>Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, PA 19104-6100

Edited by Roger Y. Tsien, University of California at San Diego, La Jolla, CA, and approved October 18, 1998 (received for review July 31, 1998)

**ABSTRACT** Inositol 1,4,5-tris-phosphate ( $\text{IP}_3$ ) binding to its receptors ( $\text{IP}_3\text{R}$ ) in the endoplasmic reticulum (ER) activates  $\text{Ca}^{2+}$  release from the ER lumen to the cytoplasm, generating complex cytoplasmic  $\text{Ca}^{2+}$  concentration signals including temporal oscillations and propagating waves.  $\text{IP}_3$ -mediated  $\text{Ca}^{2+}$  release is also controlled by cytoplasmic  $\text{Ca}^{2+}$  concentration with both positive and negative feedback. Single-channel properties of the  $\text{IP}_3\text{R}$  in its native ER membrane were investigated by patch clamp electrophysiology of isolated *Xenopus* oocyte nuclei to determine the dependencies of  $\text{IP}_3\text{R}$  on cytoplasmic  $\text{Ca}^{2+}$  and  $\text{IP}_3$  concentrations under rigorously defined conditions. Instead of the expected narrow bell-shaped cytoplasmic free  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_i$ ) response centered at  $\approx 300$  nM–1  $\mu\text{M}$ , the open probability remained elevated ( $\approx 0.8$ ) in the presence of saturating levels (10  $\mu\text{M}$ ) of  $\text{IP}_3$ , even as  $[\text{Ca}^{2+}]_i$  was raised to high concentrations, displaying two distinct types of functional  $\text{Ca}^{2+}$  binding sites: activating sites with half-maximal activating  $[\text{Ca}^{2+}]_i$  ( $K_{\text{act}}$ ) of 210 nM and Hill coefficient ( $H_{\text{act}}$ )  $\approx 2$ ; and inhibitory sites with half-maximal inhibitory  $[\text{Ca}^{2+}]_i$  ( $K_{\text{inh}}$ ) of 54  $\mu\text{M}$  and Hill coefficient ( $H_{\text{inh}}$ )  $\approx 4$ . Lowering  $\text{IP}_3$  concentration was without effect on  $\text{Ca}^{2+}$  activation parameters or  $H_{\text{inh}}$ , but decreased  $K_{\text{inh}}$  with a functional half-maximal activating  $\text{IP}_3$  concentration ( $K_{\text{IP}_3}$ ) of 50 nM and Hill coefficient ( $H_{\text{IP}_3}$ ) of 4 for  $\text{IP}_3$ . These results demonstrate that  $\text{Ca}^{2+}$  is a true receptor agonist, whereas the sole function of  $\text{IP}_3$  is to relieve  $\text{Ca}^{2+}$  inhibition of  $\text{IP}_3\text{R}$ . Allosteric tuning of  $\text{Ca}^{2+}$  inhibition by  $\text{IP}_3$  enables the individual  $\text{IP}_3\text{R}$   $\text{Ca}^{2+}$  channel to respond in a graded fashion, which has implications for localized and global cytoplasmic  $\text{Ca}^{2+}$  concentration signaling and quantal  $\text{Ca}^{2+}$  release.

Modulation of cytoplasmic free  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_i$ ) is involved in the regulation of numerous cell physiological processes in which the second messenger inositol 1,4,5-tris-phosphate ( $\text{IP}_3$ ) plays a central role in most cell types (1). Binding of extracellular ligands to G protein- or tyrosine kinase-linked receptors in the plasma membrane activates phospholipase C to generate  $\text{IP}_3$ , which binds to its receptors ( $\text{IP}_3\text{R}$ ) in the endoplasmic reticulum (ER), activating them as  $\text{Ca}^{2+}$  channels to release stored  $\text{Ca}^{2+}$  from the ER lumen into the cytoplasm. The complex control of  $[\text{Ca}^{2+}]_i$  is manifested temporally as repetitive spikes or oscillations (with frequencies often tuned to the level of stimulation) and spatially as propagating waves (1–3) and displays “adaptation” and “quantal release”, which are poorly understood (4, 5).  $\text{IP}_3$ -mediated  $\text{Ca}^{2+}$  release is regulated by  $[\text{Ca}^{2+}]_i$ , with positive and negative feedback acting in a bell-shaped manner with peak  $\text{Ca}^{2+}$  release activity at  $\approx 300$  nM  $\text{Ca}^{2+}$  (6, 7); however, the mechanisms underlying this biphasic response—a fundamental component of  $[\text{Ca}^{2+}]_i$  oscillations and wave propagation mod-

els (1, 3, 8)—are still poorly defined. The intracellular location of the  $\text{IP}_3\text{R}$  channel has necessitated the use of indirect measurements to infer its activity and has restricted studies of its single-channel properties (9–11). For this report, we systematically investigated the dependencies of single  $\text{IP}_3\text{R}$  channels on  $[\text{Ca}^{2+}]_i$  and  $\text{IP}_3$  concentration under rigorously defined conditions by using nuclear patch clamp of the  $\text{IP}_3\text{R}$  in its native ER membrane environment (12–15). Our results provide insights into the mechanism of channel activation by  $\text{IP}_3$ : whereas  $\text{Ca}^{2+}$  is a true receptor agonist, the sole function of  $\text{IP}_3$  is to relieve  $\text{Ca}^{2+}$  inhibition of the channel. Ligand tuning of feedback inhibition by the permeant ion endows individual  $\text{IP}_3\text{R}$   $\text{Ca}^{2+}$  channels with the ability to respond in a graded fashion to stimulus intensity.

## METHODS

Patch clamp of the outer membrane of individual nuclei mechanically isolated from *Xenopus laevis* oocytes was performed as described (12–14). The oocyte expresses only a single  $\text{IP}_3\text{R}$  isoform (type 1) and lacks other (e.g., ryanodine receptor)  $\text{Ca}^{2+}$  release channels (16). The cytoplasmic aspect of the  $\text{IP}_3\text{R}$  channel faced into the patch pipette. All experimental solutions contained 140 mM KCl, 10 mM Hepes (pH adjusted to 7.1 with KOH), and 0 or 0.5 mM  $\text{Na}_2\text{ATP}$  as indicated. By using  $\text{K}^+$  as the current carrier and appropriate quantities of the high-affinity  $\text{Ca}^{2+}$  chelator 1,2-bis(2-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid (BAPTA), the low-affinity  $\text{Ca}^{2+}$  chelator, 5,5'-dibromoBAPTA, or ATP alone to buffer  $\text{Ca}^{2+}$  in the experimental solutions, concentrations were tightly controlled in our experiments. Total  $\text{Ca}^{2+}$  content in the solutions was determined by induction-coupled plasma mass spectrometry (Mayo Medical Laboratory, Rochester, MN). Free  $\text{Ca}^{2+}$  concentrations were calculated by using the MAXCHELATOR software (C. Patton, Stanford University, Palo Alto, CA). Pipette solutions contained various concentrations of  $\text{IP}_3$  as stated. All experiments were performed at room temperature with the pipette electrode at +20 mV relative to the reference-bath electrode. Each data point shown is the mean of results from at least four separate patch-clamp experiments performed under the same conditions. Error bars indicate the SEM. Single-channel currents were amplified by an Axopatch-1D amplifier (Axon Instruments, Foster City, CA), filtered at 1 kHz, digitized at 5 kHz, and recorded directly on hard disk by using Pulse+PulseFit 8.02 (HEKA Electronics, Lambrecht/Pfalz, Germany) on a PowerMac 8100 with an ITC-16 interface (Instrutech, Great Neck, NY). Channel dwell times and  $P_o$ s were obtained by

This paper was submitted directly (Track II) to the *Proceedings* office. Abbreviations:  $\text{IP}_3$ , inositol 1,4,5-tris-phosphate;  $\text{IP}_3\text{R}$ ,  $\text{IP}_3$  receptor;  $[\text{Ca}^{2+}]_i$ , cytoplasmic free  $\text{Ca}^{2+}$  concentration;  $P_o$ , open probability; ER, endoplasmic reticulum; BAPTA, 1,2-bis(2-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid.

<sup>‡</sup>To whom reprint requests should be addressed at: Department of Physiology and Institute for Human Gene Therapy, Stellar Chance Laboratories, Room 313B/6100, University of Pennsylvania, Philadelphia, PA 19104-6100. e-mail: foskett@mail.med.upenn.edu.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

© 1998 by The National Academy of Sciences 0027-8424/98/9515821-5\$2.00/0 PNAS is available online at www.pnas.org.

using TAC 3.03 (Bruyton, Seattle, WA). Data were fitted and modeled by using IGOR PRO 3.12 (WaveMetrics, Lake Oswego, OR).

## RESULTS AND DISCUSSION

**[Ca<sup>2+</sup>]<sub>i</sub> Dependence of the Gating of the IP<sub>3</sub>R Channel.** To examine the effects of [Ca<sup>2+</sup>]<sub>i</sub> on IP<sub>3</sub>R channel activity without possible Ca<sup>2+</sup> effects on IP<sub>3</sub> binding, a functionally saturating IP<sub>3</sub> concentration of 10 μM (17) was applied to the cytoplasmic (pipette) side of the channel to fully stimulate it at various [Ca<sup>2+</sup>]<sub>i</sub>. With [Ca<sup>2+</sup>]<sub>i</sub> corresponding to resting levels in cells (10–100 nM), the P<sub>o</sub> of the IP<sub>3</sub>R was low (<0.2, Fig. 1 *a* and *c*), with short open intervals (τ<sub>o</sub> < 3 ms) separated by long closed intervals (τ<sub>c</sub> ≈ 100 ms; Fig. 1*b*). When [Ca<sup>2+</sup>]<sub>i</sub> was increased from 100 nM to 1 μM, P<sub>o</sub> increased dramatically to 0.8 as the result of a marked decrease of τ<sub>c</sub> to ≈2 ms, whereas τ<sub>o</sub> increased moderately to ≈10 ms. Similar [Ca<sup>2+</sup>]<sub>i</sub> in the absence of IP<sub>3</sub> did not activate the channel (data not shown). Because saturating IP<sub>3</sub> concentrations were used, the Ca<sup>2+</sup> requirement is not caused by Ca<sup>2+</sup> enhancement of IP<sub>3</sub> affinity (18). Surprisingly, instead of the expected narrow bell-shaped [Ca<sup>2+</sup>]<sub>i</sub> response centered at ≈300 nM–1 μM (9, 10, 15, 19), P<sub>o</sub> remained very high (≈0.8) even as [Ca<sup>2+</sup>]<sub>i</sub> was raised to quite high levels (1–20 μM); with long open bursts lasting >1 sec, during which the channel only closed very briefly. As [Ca<sup>2+</sup>]<sub>i</sub> was increased beyond 20 μM, P<sub>o</sub> decreased sharply, mainly the result of τ<sub>c</sub> increasing to ≈100 ms, whereas τ<sub>o</sub> decreased to ≈1 ms. In the presence of saturating concentrations of IP<sub>3</sub>, there were no systematic effects on the P<sub>o</sub>-vs.-[Ca<sup>2+</sup>]<sub>i</sub> response of the species or concentration of Ca<sup>2+</sup> chelator used (Fig. 1*c*), or the luminal Ca<sup>2+</sup> (between 0.2 and 1.5 μM) or ATP (0 or 0.5 mM; Fig. 1*d*) concentrations.

The IP<sub>3</sub>R P<sub>o</sub>-vs.-[Ca<sup>2+</sup>]<sub>i</sub> response in 10 μM IP<sub>3</sub> could be fitted to a biphasic Hill equation (Fig. 1*c*) so that:

$$P_o = P_{\max} \left\{ 1 + \left( \frac{K_{\text{act}}}{[\text{Ca}^{2+}]_i} \right)^{H_{\text{act}}} \right\}^{-1} \left\{ 1 + \left( \frac{[\text{Ca}^{2+}]_i}{K_{\text{inh}}} \right)^{H_{\text{inh}}} \right\}^{-1} \quad [1]$$

This suggests that a tetrameric IP<sub>3</sub>R channel can achieve a maximum open probability P<sub>max</sub> of 0.81, with two distinct types of functional Ca<sup>2+</sup> binding sites, activating sites with half-maximal activating [Ca<sup>2+</sup>]<sub>i</sub>, K<sub>act</sub>, of 210 ± 20 nM and Hill coefficient H<sub>act</sub> of 1.9 ± 0.3, and inhibitory sites with half-maximal inhibitory [Ca<sup>2+</sup>]<sub>i</sub>, K<sub>inh</sub>, of 54 ± 3 μM and Hill coefficient H<sub>inh</sub> of 3.9 ± 0.7. The large Hill coefficients, H<sub>act</sub> and H<sub>inh</sub>, indicate that activation and inhibition of the IP<sub>3</sub>R by Ca<sup>2+</sup> are both highly cooperative processes and suggest a requirement for Ca<sup>2+</sup> binding to two of four monomers to open the channel in the presence of IP<sub>3</sub> and for Ca<sup>2+</sup> binding to all four monomers to inhibit channel opening.

**IP<sub>3</sub> Dependence of the [Ca<sup>2+</sup>]<sub>i</sub> Sensitivity.** The striking insensitivity of P<sub>o</sub> to increases of [Ca<sup>2+</sup>]<sub>i</sub> until quite high levels results in a P<sub>o</sub>-vs.-[Ca<sup>2+</sup>]<sub>i</sub> curve with a broad plateau. Previous models of complex temporal and spatial [Ca<sup>2+</sup>]<sub>i</sub> signaling have assumed a much higher affinity of the inhibitory Ca<sup>2+</sup> binding sites than is suggested by our data. We examined whether this discrepancy arose from our use of saturating IP<sub>3</sub> concentrations. However, there was no significant change in the [Ca<sup>2+</sup>]<sub>i</sub> dependence when the IP<sub>3</sub> concentration was varied between 0.1 and 180 μM (Fig. 2). Thus, there is no evidence that the IP<sub>3</sub>R channel possesses a low-affinity IP<sub>3</sub> binding site with binding coefficient >100 nM, consistent with biochemical determinations (17, 18, 20, 21). Contrary to earlier observations (22–24), no inhibitory effects of the Ca<sup>2+</sup> chelator BAPTA on Ca<sup>2+</sup> activation of the IP<sub>3</sub>R were detected, even at low (20–33 nM) IP<sub>3</sub> concentrations (Fig. 2). At IP<sub>3</sub> concentrations <100 nM, however, the IP<sub>3</sub>R became more sensitive to Ca<sup>2+</sup> inhibition: at 33 nM IP<sub>3</sub>, K<sub>inh</sub> decreased to 9.5 μM, although H<sub>inh</sub> and Ca<sup>2+</sup> activation were not affected. Further




FIG. 1. [Ca<sup>2+</sup>]<sub>i</sub> dependence of the IP<sub>3</sub>R in the presence of 10 μM IP<sub>3</sub>. (*a*) Typical single-channel current traces of the IP<sub>3</sub>R at various [Ca<sup>2+</sup>]<sub>i</sub>. Arrows indicate closed-channel current level in all traces. (*b*) Dependence on [Ca<sup>2+</sup>]<sub>i</sub> of mean closed-channel duration τ<sub>c</sub> and open-channel duration τ<sub>o</sub> of the IP<sub>3</sub>R. (*c*) Dependence of IP<sub>3</sub>R P<sub>o</sub> on [Ca<sup>2+</sup>]<sub>i</sub>. Experiments were performed with different Ca<sup>2+</sup> chelators in the pipette solutions. Bath solution contained 1.5 μM Ca<sup>2+</sup> and 0.5 mM ATP. Numerical labels indicate calculated concentrations (in μM) of free Ca<sup>2+</sup> chelators present in the pipette solutions for the corresponding data points. The solid curve is the Hill equation fit for the biphasic [Ca<sup>2+</sup>]<sub>i</sub> effect on IP<sub>3</sub>R P<sub>o</sub>. (*d*) IP<sub>3</sub>R P<sub>o</sub> vs. [Ca<sup>2+</sup>]<sub>i</sub> in various bath solutions. Small open symbols: 0.8 μM luminal [Ca<sup>2+</sup>]<sub>i</sub>, 0.5 mM ATP; large open symbols: 0.2 μM luminal [Ca<sup>2+</sup>]<sub>i</sub>, 0 ATP; solid symbols: 0.2 μM luminal [Ca<sup>2+</sup>]<sub>i</sub>, 0.5 mM ATP. Convention for symbols and the solid curve are the same as in *c*.

decreases in IP<sub>3</sub> to 10 and 20 nM caused pronounced reductions of both the maximum P<sub>o</sub> and the range of [Ca<sup>2+</sup>]<sub>i</sub> over which the IP<sub>3</sub>R was active. The enhanced Ca<sup>2+</sup> inhibition at low IP<sub>3</sub> concentrations cannot be explained by inhibition of IP<sub>3</sub> binding, because a ≈300-fold increase in [Ca<sup>2+</sup>]<sub>i</sub> (from 1 to 300 μM) was required to counter the effect of only a 5-fold increase in IP<sub>3</sub> from 20 to 100 nM, indicating that the IP<sub>3</sub> relief of [Ca<sup>2+</sup>]<sub>i</sub> inhibition is a highly cooperative process.

The measured P<sub>o</sub> at all concentrations of IP<sub>3</sub> were fitted well by using the biphasic Hill equation (1), with K<sub>inh</sub> being the only IP<sub>3</sub>-concentration-sensitive parameter (Fig. 2). Even the observed reductions of maximum P<sub>o</sub> and the range of [Ca<sup>2+</sup>]<sub>i</sub> over




FIG. 2. IP<sub>3</sub>-concentration dependence of the [Ca<sup>2+</sup>]<sub>i</sub> sensitivity of the IP<sub>3</sub>R. Different symbols denote data for various IP<sub>3</sub> concentrations as tabulated. Data points for 10 μM IP<sub>3</sub> were combined from experiments using various bath solutions with the same pipette [Ca<sup>2+</sup>]. Data points for other concentrations of IP<sub>3</sub> were obtained in bath solutions containing 220 nM Ca<sup>2+</sup> and no ATP. The curves are Hill equation fits using Eq. 1, with K<sub>inh</sub> varying with IP<sub>3</sub> concentration with values as listed in the graph, whereas P<sub>max</sub>, K<sub>act</sub>, H<sub>act</sub>, and H<sub>inh</sub> remained independent of IP<sub>3</sub> concentration, with the values tabulated in the graph. Numerical labels indicate calculated concentrations (in μM) of free Ca<sup>2+</sup> chelator BAPTA present in pipette solutions used for the corresponding data points.

which the channel is active at very low IP<sub>3</sub> concentrations can both be accounted for in this model by a continuous decrease in K<sub>inh</sub> with decreasing IP<sub>3</sub>, whereas the other parameters: P<sub>max</sub>, K<sub>act</sub>, H<sub>act</sub>, and H<sub>inh</sub> all remain unchanged by IP<sub>3</sub> concentration. These data lead to an unexpected conclusion: the effect of IP<sub>3</sub> binding is not to enable activation of the IP<sub>3</sub>R by Ca<sup>2+</sup>, as expected for co-agonist ligands and as generally assumed (17, 18, 20, 21), but rather it is to ameliorate inhibition of the channel by Ca<sup>2+</sup>. The derived values of K<sub>inh</sub> ranged from 160 nM at 10 nM IP<sub>3</sub> to 59 μM at 100 nM IP<sub>3</sub>. This IP<sub>3</sub> dependence of K<sub>inh</sub> was well fitted with a simple Hill equation so that

$$K_{inh} = K_{\infty} \left\{ 1 + \left( \frac{K_{IP_3}}{[IP_3]} \right)^{H_{IP_3}} \right\}^{-1} \quad [2]$$

This equation, represented in Fig. 3a, implies that the IP<sub>3</sub>R has a single class of functional IP<sub>3</sub> binding sites with a half-maximal activating IP<sub>3</sub> concentration, K<sub>IP<sub>3</sub></sub>, of 50 ± 4 nM, a Hill coefficient H<sub>IP<sub>3</sub></sub> of 4 ± 0.5, and a maximum inhibitory Ca<sup>2+</sup> binding coefficient K<sub>∞</sub> of 52 ± 4 μM at a saturating IP<sub>3</sub> concentration. The K<sub>IP<sub>3</sub></sub> derived from this model is similar to both the dissociation constant K<sub>D</sub> (10–100 nM) in IP<sub>3</sub> binding assays and IP<sub>3</sub> concentration required (≈10–100 nM) for stimulation of Ca<sup>2+</sup> release (17, 20, 21, 25). The large Hill coefficient H<sub>IP<sub>3</sub></sub> of 4 indicates that IP<sub>3</sub> activation of the IP<sub>3</sub>R is highly cooperative (25–28) even in the absence of positive feedback from cytoplasmic Ca<sup>2+</sup>, requiring IP<sub>3</sub> binding to perhaps all four monomers of the channel to relieve the Ca<sup>2+</sup> inhibition and gate the channel open. Because IP<sub>3</sub> binding to the IP<sub>3</sub>R is not cooperative (17, 18, 20, 21), the similar Hill coefficients H<sub>IP<sub>3</sub></sub> and H<sub>inh</sub> (both ≈4) may suggest that IP<sub>3</sub> binding to each IP<sub>3</sub>R monomer influences the inhibitory Ca<sup>2+</sup> site in that same monomer.

According to these results, cytoplasmic Ca<sup>2+</sup> at low concentrations and IP<sub>3</sub> both activate the IP<sub>3</sub>R channel (Fig. 4), but they affect the channel in fundamentally different ways. Ca<sup>2+</sup> binding

to the IP<sub>3</sub>R at low [Ca<sup>2+</sup>]<sub>i</sub> directly activates the channel—like a conventional agonist. In contrast, IP<sub>3</sub> binding to the channel activates it indirectly, solely by decreasing the affinity of the Ca<sup>2+</sup> inhibitory site, with no direct stimulatory effect itself. Under conditions of low IP<sub>3</sub> concentration, Ca<sup>2+</sup> preferentially binds to the inhibitory site because of its higher affinity (K<sub>inh</sub> < K<sub>act</sub>), causing the channel to be inactive. Under conditions of stimula-




FIG. 3. (a) Dependence on IP<sub>3</sub> concentration of K<sub>inh</sub> as derived from Fig. 2. The curve is a simple Hill equation fit. (b) Bell-shaped normalized P<sub>o</sub>-vs-[Ca<sup>2+</sup>]<sub>i</sub> curves calculated by using Eqs. 1 and 2 for various low concentrations of IP<sub>3</sub> (dotted curve, 10 nM IP<sub>3</sub> with maximum P<sub>o</sub> of 0.09; dashed curve, 15 nM IP<sub>3</sub> with maximum P<sub>o</sub> of 0.49; and solid curve, 20 nM IP<sub>3</sub> with maximum P<sub>o</sub> of 0.71). (c) Theoretical P<sub>o</sub> (calculated by using the model) vs. IP<sub>3</sub> concentration at various [Ca<sup>2+</sup>]<sub>i</sub>, as labeled. Dashed curves, [Ca<sup>2+</sup>]<sub>i</sub> ≤ 1 μM; thin solid curves, [Ca<sup>2+</sup>]<sub>i</sub> ≥ 10 μM.






FIG. 4. Calculated  $P_o$  vs.  $[Ca^{2+}]_i$  and  $IP_3$  concentration according to our model. (a) Projection showing  $P_o$ -vs.- $IP_3$  concentration curves at various activating  $[Ca^{2+}]_i$ . (b) Projection showing  $P_o$ -vs.- $[Ca^{2+}]_i$  curves at various  $IP_3$  concentrations. (c) Projection showing  $P_o$  vs.  $IP_3$  concentration curves at various inhibitory  $[Ca^{2+}]_i$ .

tion associated with higher  $IP_3$  concentration,  $K_{inh}$  becomes  $>K_{act}$ , so  $Ca^{2+}$  binds preferentially to the  $Ca^{2+}$  activation site, activating the channel. A recent study of reconstituted  $IP_3R$  also observed an  $IP_3$  dependence of  $Ca^{2+}$  inhibition (11). However, the results and interpretations are fundamentally different from ours. First, the  $IP_3$  required to observe relief from  $Ca^{2+}$  inhibition was  $\approx 180 \mu M$ , three orders of magnitude higher than that measured here. Furthermore,  $P_{max}$  was 0.03 vs. 0.81 in our studies. Second, inhibitory effects of  $Ca^{2+}$  on the channel were not observed at 180  $\mu M$   $IP_3$ , in contrast to our results. Third, an additional low-affinity (10  $\mu M$ )  $IP_3$  binding site was invoked to account for the  $IP_3$  relief of  $Ca^{2+}$  inhibition, whereas our data indicate that only one functional  $IP_3$  binding site is involved, with the affinity expected ( $\approx 50$  nM) from biochemical studies. Importantly, our data indicate that  $IP_3$  mediates its effects by modulating the affinity of  $Ca^{2+}$  inhibitory sites, which is conceptually distinct from agonist activity caused by  $IP_3$  binding to a second low affinity site.

**Implications for  $IP_3$ -Mediated  $[Ca^{2+}]_i$  Signaling.** Our results provide another interpretation of the role of  $IP_3$ , thus warranting reconsideration of previous observations of  $IP_3$ -mediated  $[Ca^{2+}]_i$  signals in cells. Our model predicts a bell-shaped relationship between  $P_o$  and  $[Ca^{2+}]_i$ , with a sharp peak at  $[Ca^{2+}]_i < 1 \mu M$  (9, 15, 19), although only under conditions of low ( $< 20$  nM)  $IP_3$  (Fig. 4b). The low  $P_o$  and the bell shape, as well as the range of  $[Ca^{2+}]_i$  over which the channel is active observed for reconstituted  $IP_3R$  channels at high (2  $\mu M$ )  $IP_3$  (9–11), are remarkably similar to the predicted channel behaviors according to our model, albeit at much lower ( $IP_3 \approx 10$  nM) concentration, suggesting an  $IP_3$  insensitivity of the reconstituted channels in those studies. Although neither the  $IP_3$  binding coefficient  $K_{IP_3}$  nor the Hill coefficient  $H_{IP_3}$  is  $[Ca^{2+}]_i$ -dependent in our model, the interplay between the effects of  $[Ca^{2+}]_i$  and  $IP_3$  concentration on  $P_o$  can be manifested as an apparent increase in  $IP_3$  sensitivity as  $[Ca^{2+}]_i$  decreases at low  $[Ca^{2+}]_i$  (Fig. 3c) and an apparent decrease in cooperativity of  $IP_3$  activation as  $[Ca^{2+}]_i$  increases (Fig. 3c). Thus, our results may qualitatively explain previous observations that submicromolar  $[Ca^{2+}]_i$  lowered the functional sensitivity of the  $IP_3R$  for  $IP_3$  (29, 30) and that the Hill coefficient for  $IP_3$  activation of  $Ca^{2+}$  release decreased as  $[Ca^{2+}]_i$  increased from the submicromolar to tens of  $\mu M$  range (27, 28, 31).

A major paradox has been  $[Ca^{2+}]_i$  responses that are graded in proportion to the intensity of the stimulus, because the process of  $Ca^{2+}$ -induced  $Ca^{2+}$  release should lead to an all-or-none signal (32, 33). One proposed mechanism suggests that increased  $IP_3$  concentration recruits more individual elementary release units that each contribute a quantized amount of  $Ca^{2+}$  (32–35). Our model suggests another mechanism for achieving graded responses involving the  $IP_3R$  itself. Because  $IP_3$  binding to the  $IP_3R$  relieves  $Ca^{2+}$  inhibition of the channel, higher  $IP_3$  concentration shifts the peak of the  $P_o$ -vs.- $[Ca^{2+}]_i$  curve to higher  $[Ca^{2+}]_i$  (Fig. 3b). A  $[Ca^{2+}]_i$  that

can inhibit channel activity at low  $IP_3$  will be insufficient to inhibit it when  $IP_3$  is increased (Fig. 4b). Higher  $[Ca^{2+}]_i$  at the mouth of the channel pore can therefore be achieved before reaching levels that terminate release. This process therefore generates graded  $Ca^{2+}$  release from  $IP_3$ -sensitive stores through a mechanism intrinsic to the individual  $IP_3R$ . By enabling higher  $[Ca^{2+}]_i$  to be achieved at the mouth of individual channels, higher  $IP_3$  concentration associated with more intense stimuli would promote greater diffusive spread of the local  $[Ca^{2+}]_i$  signal to other sites, thereby transforming highly localized signals at low levels of stimulation to more global coordinated  $Ca^{2+}$  release signals as the intensity of the stimulus is increased, without the need to invoke channels with different  $IP_3$  sensitivities or clusters of higher channel densities (13, 32–34), although our results in no way exclude these or other mechanisms. By similar reasoning, our model can also account for the transformation of oscillating  $[Ca^{2+}]_i$  at relatively low levels of agonist stimulation to sustained  $[Ca^{2+}]_i$  increases during intense stimulation. Quantal  $Ca^{2+}$  release elicited by  $IP_3$  (4, 5) has been described as a unique signaling mechanism that enables cells to retain complete responsiveness to changes in stimulus intensity (36). Our model suggests that this property can be intrinsic to the  $IP_3R$ . Because our experiments investigated the steady-state properties of the  $IP_3R$ , future kinetic studies will be required to determine the relevance of this model for quantal release in cells, as well as for other aspects of  $[Ca^{2+}]_i$  signaling, including  $IP_3R$  desensitization (37) and inactivation (12, 13, 38).

We thank Dr. S. K. Joseph for reading the manuscript. This work was supported by grants from the Cystic Fibrosis Foundation and the National Institutes of Health.

- Berridge, M. J. (1993) *Nature (London)* **361**, 315–325.
- Meyer, T. & Stryer, L. (1991) *Annu. Rev. Biophys. Biophys. Chem.* **20**, 153–174.
- Toescu, E. C. (1995) *Am. J. Physiol.* **269**, G173–G185.
- Bootman, M. D. (1994) *Mol. Cell. Endocrinol.* **98**, 157–166.
- Parys, J. B., Missiaen, L., De Smedt, H., Sienaeert, I. & Casteels, R. (1996) *Pflügers Arch.* **432**, 359–367.
- Iino, M. & Tsukioka, M. (1994) *Mol. Cell. Endocrinol.* **98**, 141–146.
- Taylor, C. W. & Marshall, I. C. B. (1992) *Trends Biochem. Sci.* **17**, 403–407.
- Putney, J. W., Jr., & Bird, G. S. (1993) *Endocr. Rev.* **14**, 610–631.
- Bezprozvanny, I., Watras, J. & Ehrlich, B. E. (1991) *Nature (London)* **351**, 751–754.
- Bezprozvanny, I. & Ehrlich, B. E. (1995) *J. Membr. Biol.* **145**, 205–216.
- Kaftan, E. J., Ehrlich, B. E. & Watras, J. (1997) *J. Gen. Physiol.* **110**, 529–538.
- Mak, D.-O. D. & Foskett, J. K. (1994) *J. Biol. Chem.* **269**, 29375–29378.

13. Mak, D.-O. D. & Foskett, J. K. (1997) *J. Gen. Physiol.* **109**, 571–587.
14. Mak, D.-O. D. & Foskett, J. K. (1998) *Am. J. Physiol.* **275**, C179–C188.
15. Stehno-Bittel, L., Lückhoff, A. & Clapham, D. E. (1995) *Neuron* **14**, 163–167.
16. Kume, S., Muto, A., Aruga, J., Nakagawa, T., Michikawa, T., Furuichi, T., Nakade, S., Okano, H. & Mikoshiba, K. (1993) *Cell* **73**, 555–570.
17. Mauger, J.-P., Lièvreumont, J.-P., Piétri-Rouxel, F., Hilly, M. & Coquil, J.-F. (1994) *Mol. Cell. Endocrinol.* **98**, 133–139.
18. Taylor, C. W. & Traynor, D. (1995) *J. Membr. Biol.* **145**, 109–118.
19. Iino, M. (1990) *J. Gen. Physiol.* **95**, 1103–1122.
20. Taylor, C. W. & Richardson, A. (1991) *Pharmacol. Ther.* **51**, 97–137.
21. Joseph, S. K. (1995) *Cell. Signalling* **8**, 1–7.
22. Richardson, A. & Taylor, C. W. (1993) *J. Biol. Chem.* **268**, 11528–11533.
23. Combettes, L. & Champeil, P. (1994) *Science* **265**, 813.
24. Combettes, L., Hannaert-Merah, Z., Coquil, J.-F., Rousseau, C., Claret, M., Swillens, S. & Champeil, P. (1994) *J. Biol. Chem.* **269**, 17561–17571.
25. Meyer, T., Holowka, D. & Stryer, L. (1988) *Science* **240**, 653–655.
26. Carter, T. D. & Ogden, D. (1997) *J. Physiol. (Lond.)* **504**, 17–33.
27. Finch, E. A., Turner, T. J. & Goldin, S. M. (1991) *Science* **252**, 443–446.
28. Dufour, J. F., Arias, I. M. & Turner, T. J. (1997) *J. Biol. Chem.* **272**, 2675–2681.
29. Hirose, K., Kadowaki, S. & Iino, M. (1998) *J. Physiol. (Lond.)* **506**, 407–414.
30. Missiaen, L., De Smedt, H., Droogmans, G. & Casteels, R. (1992) *J. Biol. Chem.* **267**, 22961–22966.
31. Combettes, L., Claret, M. & Champeil, P. (1992) *FEBS Lett.* **301**, 287–290.
32. Bootman, M. D. & Berridge, M. J. (1995) *Cell* **83**, 675–678.
33. Berridge, M. J. (1997) *J. Physiol. (Lond.)* **499**, 291–306.
34. Horne, J. H. & Meyer, T. (1997) *Science* **276**, 1690–1693.
35. Callamaras, N., Marchant, J. S., Sun, X. P. & Parker, I. (1998) *J. Physiol. (Lond.)* **509**, 81–91.
36. Kindman, L. A. & Meyer, T. (1993) *Biochemistry* **32**, 1270–1277.
37. Oancea, E. & Meyer, T. (1996) *J. Biol. Chem.* **271**, 17253–17260.
38. Hajnóczky, G. & Thomas, A. P. (1994) *Nature (London)* **370**, 474–477.